Top Tweets for #Checkmate9DW
• Same population. Same OS HR. Very different biology.
• 4 doses vs 1 dose of CTLA-4 — depth or gentleness?
• In 1L HCC, regimen choice is about who the patient is, not just the curve.
#HCC #Immunotherapy #CheckMate9DW #HIMALAYA #Oncology #MedTwitter #MVOnco
• Why does immunotherapy look worse in the first few months?
• Why do patients who cross that phase live longer?
• CheckMate 9DW shows: early risk, late durable benefit — with the right patient.
#HCC #CheckMate9DW #Immunotherapy #Oncology #MedTwitter #MVOnco
@changhoon_yoo discusses subgroup analyses in Asian patients with advanced #HCC treated with #immunotherapy combinations in #SIERRA #HIMALAYA #CheckMate9DW studies #ESMOAsia25 @myESMO
Outcomes by imAEs in Asian patients with advanced #HCC treated in the phase 3 #CheckMate9DW study #ESMOAsia25 @myESMO
Caveats and Nuances of Checkmate 9DW in Advanced HCC - @tuttsakhil
@nihanthy
https://t.co/PwzlNN8sQ1
#Cancer #Medicine #Health #Oncology #OncoDaily #HCC #LiverCancer #Checkmate9DW #MedX #MedNews #MedEd
Glad to summarize recent data of nivolumab and ipilimumab for advanced #HCC from #CheckMate9DW presented at #ESMOGI25 @VJOncology @HUNIMED @HumanitasMilano
🎥@LorenzaRimassa of @HUNIMED on CheckMate 9DW: nivolumab + ipilimumab vs lenvatinib/sorafenib in advanced HCC. Now FDA/EMA-approved & ESMO-recommended standard of care
➡️https://t.co/B9W2AEklWf⬅️
This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda. Supporters have no influence over the production of content.
@myESMO #ESMOGI25 #ImmunoOnc #CTSM #TrialUpdate #HPBCsm
🚨 Landmark trial in #liver #cancer!
The phase 3 #CheckMate9DW trial shows that dual immunotherapy (nivolumab + ipilimumab) significantly improves OS vs lenvatinib/sorafenib in 1L unresectable #HCC.
📈 36-mo OS: 38% vs 24%
🧠 Durable responses
#HCC
https://t.co/7AlFbevSrX
🚨 CheckMate 9DW: In 1L unresectable HCC, nivolumab + ipilimumab improved OS vs lenvatinib/sorafenib:
🧬 Median OS: 23.7 vs 20.6 mo.
📊 36-mo OS: 38% vs 24%.
💥 Durable benefit despite early risk.
📄📖 @TheLancet
DOI 👉 https://t.co/iNnqs4FEVN
#HCC #Immunotherapy #CheckMate9DW #Oncology
GI session and advanced HCC at NOK 2025 day 2
Kristina Jankovic (@JankovicK)
https://t.co/JD3li3CwSO
#Cancer #GIOnc #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology #GI #HCC #NOK2025 #Checkmate9DW
Yesterday: FDA ☑️ Nivo/Ipi in Unresectable/Metastatic #HCC https://t.co/JQktzoGlh0 via @CancerNetwrk
☑️OS 23.7M vs. 20.6M vs lenvatinib or sorafenib (HR, 0.79; 95% CI, 0.65-0.96; P = .018).
@FDAOncology @EAHPBA #immunotherapy @bmsnews #cancer #CancerResearch #Checkmate9DW
Big week for #GIcancers, Nivo + Ipi gets @FDA approved for HCC #livercancer, just a few days after the same regimen got approval in MSI-H #coloncancer. #CheckMate9DW https://t.co/kjmsnXJSmT
#Chekmate8HW https://t.co/6wpQ4uQ9Ob
@OncoAlert @OncBrothers @OncLive @GiOncNow
Ipo/Nivo is now @US_FDA approved in uHCC 1L. Ipi 3mg/kg + Nivo 1mg/kg for 4 cycles -> Nivo alone. #CHECKMATE9DW:
- mOS of 23.7mos vs 20.6mos (HR: 0.79)
- Similar PFS, ORR: 36% vs 13%
- 18% discontinued combo due to AEs
- CrossTrial Comparison in slide 4!
#OncTwitter #GIOnc
Now that the dust has settled from #CheckMate9DW, a poll:
For a patient with advanced #HCC, CP A, PS=0, and no relevant comorbidities (no varices), which of the following will you choose most often? Assume all options are available/approved...
While the ipi/nivo tail of the curve is fantastic #HCC #CheckMate9DW you give some up at the beginning. PD was similar between arms (20% for ipi/nivo, 14% for lenva/sora)⏩tox? This first year detriment was not seen with PD1 alone (vs sora)
Most impressive data from #CheckMate9DW (frontline nivo/ipi in #HCC) is the median duration of response: 30.4 months❗️Reaffirms something we've seen time and time again⏩Anti-CTLA4 responses are the most durable
Watch as our expert panel discusses the most significant #GICancer clinical trial data from #ASCO24 & how it might impact #patientcare. 🎥 https://t.co/GToX8Qrizr
@scottrberry @GillSharlene @FlorianLordick
#ESOPEC #RENAISSANCE #ARMANI #CheckMate9DW #COLLISION #TRANSET #GIANT
A few years ago @TimothyJBrownMD showed that 1L TKI OS in HCC studies keeps improving, perhaps reflecting better care and 2L+ treatment options. Trend continues: 20.6m❗️ control OS in #CHECKMATE9DW (versus 10.7m in SHARP)
https://t.co/QhIIWw2PRD
The P3 #CheckMate9DW study (1L ipilimumab + nivolumab) is positive! Data are particularly compelling considering control arm (mostly lenva whereas others went up against sora only) and significant crossover to 2L IO from the control arm. #HCC #ASCO2024
CheckMate 9DW by Robert Galle
Nivo+Ipi- vs Lenva/Sorafenib in 1st line uHCC
⬆️A significant OS benefit (23.7 vs 20.6 months)
✅Consistent benefit in subgroup analyses
✅Reduced risk of symptom deterioration
A new SOC in uHCC 👏
#ASCO24 #OncoAlertAF #Checkmate9DW @OncoAlert
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.6M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82.1M followers
Lady Gaga
@ladygaga
73.6M followers
Virat Kohli
@imvkohli
70.8M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.6M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers